Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
Document Type and Number:
WIPO Patent Application WO/2016/189876
Kind Code:
A1
Abstract:
The present invention provides a urea derivative or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea derivative or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.

Inventors:
FUJII KIYOSHI (JP)
UMEI KENTARO (JP)
TAKAHASHI HIROYASU (JP)
SHIBASAKI MITSUHITO (JP)
OHATA KOHEI (JP)
Application Number:
PCT/JP2016/002557
Publication Date:
December 01, 2016
Filing Date:
May 26, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
KYORIN SEIYAKU KK (JP)
International Classes:
C07D487/04; A61K31/4985; A61P11/00; A61P25/28; A61P35/00; A61P37/00; C07D207/273; C07D211/76; C07D263/26; C07D307/22; C07D498/04
Domestic Patent References:
WO2013071203A12013-05-16
WO2013070600A12013-05-16
WO2015079692A12015-06-04
WO2016095089A12016-06-23
WO2013063214A12013-05-02
WO2009077990A12009-06-25
WO2009077954A12009-06-25
WO2010143158A12010-12-16
WO2012077049A12012-06-14
WO2012077051A12012-06-14
WO2012066488A22012-05-24
WO2013171687A12013-11-21
WO2013171694A12013-11-21
WO2014206966A12014-12-31
WO2015007830A12015-01-22
WO2011163502A12011-12-29
WO2012125305A12012-09-20
WO2015005305A12015-01-15
WO2005047899A22005-05-26
WO2012074785A12012-06-07
WO2012109544A12012-08-16
WO2013062947A12013-05-02
WO2013070600A12013-05-16
WO2013071203A12013-05-16
WO2015009545A12015-01-22
WO2015019325A12015-02-12
Foreign References:
US0013001A1855-06-05
Other References:
MURPHY P. M. ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, 1992, pages 7637 - 7643
GAVINS F. N. E ET AL., TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 31, 2010, pages 266 - 276
CATTANEO F. ET AL., INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 14, no. 4, 2013, pages 7193 - 7230
DUFTON N ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 184, 2010, pages 2611 - 2619
LE Y ET AL., TRENDS IN IMMUNOLOGY, vol. 23, no. 11, 2002, pages 541 - 548
KRISHNAMOORTHY S, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 4, 2010, pages 1660 - 1665
LI B. Q ET AL., BLOOD, vol. 97, 2001, pages 2941 - 2947
SOGAWA Y ET AL., IMMUNOLOGY, vol. 132, 2011, pages 441 - 450
SUMMERS C ET AL., TRENDS IN IMMUNOLOGY, vol. 31, 2010, pages 318 - 324
KIM S. D ET AL., EXPERIMENTAL & MOLECULAR MEDICINE, vol. 13, no. 45, 2013, pages E40
TAE Y. M ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 188, 2012, pages 1799 - 1808
KIM S. D ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 185, 2010, pages 4302 - 4310
KIM S. D ET AL., PLOS ONE, vol. 7, no. 1, pages E30522
MIN H. E ET AL., ACTA PHARMACOLOGIC A SINICA, vol. 32, 2011, pages 601 - 610
NANAMORI M ET AL., MOLECULAR PHARMACOLOGY, vol. 66, 2004, pages 1213 - 1222
BURLI R. W ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16, 2006, pages 3713 - 3718
FROHN M ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, 2007, pages 6633 - 6637
CILIBRIZZI A ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, 2009, pages 5044 - 5057
KIRPOTINA L. N ET AL., MOLECULAR PHARMACOLOGY, vol. 77, 2010, pages 159 - 170
SCHEPETKIN I. A ET AL., MOLECULAR PHARMACOLOGY, vol. 79, 2011, pages 77 - 90
Attorney, Agent or Firm:
SAMEJIMA, Mutsumi et al. (Umeda Hankyu Bldg. Office Tower 8-1, Kakuda-cho, Kita-ku, Osaka-sh, Osaka 17, JP)
Download PDF: